Consent to the Distribution of Changed Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Lamotrigine 25mg Tablet, chewable/dispersible Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom; Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia; and Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Lamictal Lamotrigine 5mg Tablet, chewable/dispersible Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom; and Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom Lamictal Lamotrigine 50mg, 100mg, 200mg Tablets, chewable/dispersible Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom; and Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia Lamictal Nimodipine 30mg Tablet,film coated Bayer AG., Leverkusen, Germany Nimotop Nimodipine 0.2mg/mL Infusion, solution Bayer AG., Leverkusen, Germany Nimotop Naltrexone hydrochloride 50mg Tablet,film coated Du Pont Merck Pharmaceuticals Co., Garden City, New York, United States of America Re Via Paclitaxel 6 mg/mL Infusion, concentrate Bristol-Caribbean Inc., Mayaguez, Puerto Rico Taxol Dated this 11th day of March 1999. GILLIAN GREW, Chief Advisor, Regulation and Safety (acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.